Zobair Qasimzadah

Zobair Qasimzadah serves as a key procurement professional within the National Institutes of Health Office of Acquisition and Logistics Operations (OALO), supporting the agency’s mission to enable cutting-edge biomedical research through strategic acquisitions of advanced scientific infrastructure. He manages complex contracting actions for high-precision laboratory equipment, electromedical devices, and specialized research services critical to life sciences innovation. His work ensures timely delivery of mission-critical instrumentation and technical capabilities to NIH-funded investigators, aligning procurement outcomes with national priorities in public health and scientific discovery. Qasimzadah maintains consistent working relationships with specialized vendors including Foreign Policy Research Institute Inc. and Ontic Engineering & Manufacturing, Inc., both of which provide niche research support and high-accuracy manufacturing services. His contracting patterns reflect a preference for technical partners with demonstrated expertise in biotechnology R&D and biological product manufacturing, fostering long-term vendor collaborations grounded in compliance, performance, and scientific alignment rather than volume-driven sourcing. His procurement portfolio exhibits no set-aside preferences, with 100% of awards issued under full and open competition. This reflects a strategic focus on technical capability and mission suitability over socioeconomic categorization, prioritizing the most qualified offerors regardless of business size or certification status. While small business participation is not formally incentivized, vendor selection remains grounded in competitive evaluation criteria emphasizing technical merit and past performance. Qasimzadah’s primary contracting focus centers on NAICS 541714 (Research and Development in Biotechnology) and NAICS 325414 (Biological Product Manufacturing), reflecting deep specialization in procuring advanced biotech R&D services and non-diagnostic biological production systems. He routinely handles acquisitions for recombinant protein synthesis platforms, cell culture systems, automated bioprocessing equipment, and precision manufacturing components essential to therapeutic development and translational research.